Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News 180 Life Sciences Corp ATNF

Technology Information Technology Services
180 Life Sciences Corp. is a clinical-stage biotechnology company focused on the development of therapeutics for unmet medical needs in chronic pain, inflammation and fibrosis. The Company is primary focused on program to treat several inflammatory disorders using anti-TNF (tumor necrosis factor). The Company has three product development platforms: Anti-TNF platform, SCAs platform and a7nAChR... see more

Recent & Breaking News (NDAQ:ATNF)

180 Life Sciences with the University of Oxford Announce the Enrollment of the First Patient in a Trial of Anti-TNF for People with Early-Stage Frozen Shoulder

GlobeNewswire August 22, 2022

180 Life Sciences Announces That the University of Oxford Has Been Awarded a Grant From the National Institute for Health and Care Research in the U.K. to Conduct a Clinical Trial in Post Operative Delirium/Cognitive Deficit in a Jointly Funded Program With 180 Life Sciences Corp.

GlobeNewswire July 27, 2022

180 Life Sciences Corp. Announces Closing of $6.5 Million Registered Direct Offering

GlobeNewswire July 21, 2022

180 Life Sciences Corp. Announces $6.5 Million Registered Direct Offering

GlobeNewswire July 18, 2022

180 Life Sciences Corp. Issues Letter to Stockholders

GlobeNewswire June 22, 2022

180 Life Sciences Provides Update on Correspondence Received from U.K. and U.S. Regulatory Authorities on Pathway for a Therapy That Could Prevent Progression of Early-Stage Dupuytren's Disease

GlobeNewswire June 14, 2022

180 Life Sciences Begins Consultations with UK and US Regulatory Authorities on Pathway for a Therapy that Could Prevent Progression of Early-Stage Dupuytren's Disease

GlobeNewswire May 31, 2022

REPEAT - 180 Life Sciences and University of Oxford Announce Publication of Positive Phase 2b Dupuytren's Disease Study Results in The Lancet Rheumatology

GlobeNewswire May 2, 2022

180 Life Sciences and University of Oxford Announce Publication of Positive Phase 2b Dupuytren's Disease Study Results in The Lancet Rheumatology

GlobeNewswire April 29, 2022

180 Life Sciences Corp. Forms Scientific Advisory Board

GlobeNewswire February 17, 2022

180 Life Sciences Corp. CEO James Woody, MD, PhD Issues Letter to Shareholders

GlobeNewswire January 31, 2022

180 Life Sciences Corp. To Participate in the Biotech Showcase 2022 Virtual Conference To be Held January 10-12, 2022

GlobeNewswire December 28, 2021

180 Life Sciences Corp. Enters into a License Agreement with University of Oxford for Regenerative Molecule HMGB1 for Liver Diseases

GlobeNewswire December 15, 2021

180 Life Sciences Provides Follow-Up Information on Oxford University and the Company's Successful Dupuytren's Phase 2b Clinical Trial Results

GlobeNewswire December 6, 2021

180 Life Sciences Corp. Co-Founder Prof. Jagdeep Nanchahal Presents Keynote Address at the 2021 International Dupuytren Symposium, Including Top Line Data From the Phase 2b Clinical Trial

GlobeNewswire December 1, 2021

180 Life Sciences Corp. Expands Patent Portfolio

GlobeNewswire November 22, 2021

180 Life Sciences Corp. Co-Founder Prof. Jagdeep Nanchahal to Present a Keynote Address at the 2021 International Dupuytren Symposium 

GlobeNewswire November 18, 2021

180 Life Sciences Corp. Names Quan A. Vu Chief Operating Officer/Chief Business Officer

GlobeNewswire November 3, 2021

180 Life Sciences Corp. Publishes Pre-Clinical Study Report on the Effects of CBG Derivatives on Pain, Inflammation and Obesity in The Journal Molecules

GlobeNewswire October 26, 2021

180 Life Sciences Corp. Continues To Expand Intellectual Property Portfolio

GlobeNewswire September 30, 2021